Real-World study tracks Nivolumab's impact on advanced stomach and esophageal cancers
NCT ID NCT07663786
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how the immunotherapy drug nivolumab is used in routine care for adults with advanced cancers of the esophagus, gastroesophageal junction, or stomach. Researchers will analyze data from a Dutch cancer registry to see how long people live after starting nivolumab and what factors affect their outcomes. The goal is to understand how well the drug works outside of clinical trials, in everyday hospital settings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab
What this could lead to
If successful, this could show how well nivolumab works in everyday practice for advanced stomach and esophageal cancers, helping doctors make better treatment decisions.
What could go wrong
This is an observational study using existing data, not a controlled trial. It cannot prove cause and effect, and results may be influenced by factors like patient selection or missing information.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Amsterdam UMC
Amsterdam, Netherlands